Dublin, March 13, 2024 (GLOBE NEWSWIRE) -- The "Global Anxiety Disorders And Depression Treatment Market Analysis & Forecast…
For Medical and Trade media.
· Foslevodopa-foscarbidopa will soon be available for eligible patients with advanced levodopa-responsive Parkinson’s disease…
…
The FDA grants priority review status to Sanofis (SNY) and AbbVies (ABBV) sBLAs for Dupixent and Epkinly, respectively…
AbbVie and OSE Immunotherapeutics ink $713M deal…
Healthcare is one of the worlds most critical sectors, and healthcare stocks offer an opportunity to invest in companies that…
Pharmaceutical giant AbbVie Inc. is selling around $15 billion of bonds in the US investment-grade market on Thursday to help…
AbbVie eyes selling at least $13 billion of bonds to fund M&A, Bloomberg reports…
Pharmaceutical giant AbbVie Inc. is looking to sell at least $13 billion of corporate bonds to help fund its acquisitions…
Wien (www.aktiencheck.de) - AbbVie-Aktienanalyse von der Raiffeisen Bank International AG:
Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI), nimmt in…
Robert Michael is set to succeed Richard A. Gonzalez as AbbVies (ABBV) CEO, effective Jul 1, 2024.…
Michael, who is AbbVies chief operating officer, will become the companys second-ever CEO since the company spun out from Abbott…
AbbVie names Robert A. Michael as new CEO…
…
AbbVie Inc.’s stock fell 0.5% early Monday, after the biotech lowered its first-quarter guidance to reflect the dilutive impact of…
Todays Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Applied Materials, Inc. (AMAT) and…
The drugmaker is handling its biggest obstacle yet relatively well.…
The pharmaceutical industry is a major player in the life science sector, responsible for developing and manufacturing the majority of…
…
Heres what could happen to AbbVies shares next.…
Both offer above-average yields but which can deliver the most dividend income over the long run?…
…
Wien (www.aktiencheck.de) - AbbVie (ISIN: US00287Y1091, WKN: A1J84E, Ticker-Symbol: 4AB, NYSE-Symbol: ABBV) (+0,6%) stellte ebenfalls am Freitag seine Jahreszahlen vor,…
ABBV earnings call for the period ending December 31, 2023.…
…
…
Morning Meeting updates on stocks outside the Club portfolio: Clorox, Tesla, Bristol-Myers, Abbvie, Exxon and Chevron.…
Drugmakers Bristol-Myers Squibb Co (NYSE:BMY, ETR:RM, OTC:BMYMP) and Abbvie Inc (NYSE:ABBV) on Friday both reported better than expected financial results...…
Wien (www.aktiencheck.de) - AbbVie-Aktienanalyse von der Raiffeisen Bank International AG:
Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI), nimmt in…
AbbVie tops Q4 earnings, revenue consensus estimate…
AbbVie earnings beat by $0.02, revenue topped estimates…
…
AbbVie on Friday reported fourth-quarter sales that topped analyst estimates, even as it faces low-cost competition for its top-seller Humira.…
AbbVie earnings missed by $0.04, revenue topped estimates…
…
AbbVie profit beats estimates as Humira, Botox sales weather hit from rivals…
Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk…
Frankfurt (Reuters) - Der US-Pharmakonzern AbbVie profitiert von einer hohen Nachfrage nach seinem Blockbuster-Medikament Humira und der Übernahme des Botox-Herstellers…
Bangalore (Reuters) - Deutschlands zweitgrößter Pharmakonzern Boehringer Ingelheim steht einem Agenturbericht zufolge vor einer umfassenden Partnerschaft bei Krebs-Therapien mit dem…